Table 1.
Patient Characteristics
| 2000–2004 | 2005–2009 | 2010–2014 | 2015–2018 | |
|---|---|---|---|---|
|
| ||||
| No. of patients | 331 | 1283 | 1922 | 1546 |
|
| ||||
| No. of centers | 99 | 126 | 136 | 130 |
|
| ||||
| Age at diagnosis, years - n (%) | ||||
|
| ||||
| Median (range) | 57 (32–73) | 59 (23–78) | 59 (23–78) | 59 (24–78) |
|
| ||||
| < 65 | 285 (86) | 984 (77) | 1493 (78) | 1170 (76) |
|
| ||||
| Age at HCT, years - n (%) | ||||
| Median (range) | 57 (32–73) | 59 (24–78) | 60 (23–78) | 60 (24–78) |
| 60–69 | 103 (31) | 496 (39) | 833 (43) | 662 (43) |
| ≥ 70 | 13 (4) | 102 (8) | 124 (6) | 116 (8) |
|
| ||||
| Male gender - n (%) | 249 (75) | 987 (77) | 1450 (75) | 1172 (76) |
|
| ||||
| KPS - n (%) | ||||
| ≥ 90 | 21 (6) | 438 (34) | 1342 (70) | 1032 (67) |
| < 90 | 238 (72) | 571 (45) | 541 (28) | 502 (32) |
| Missing | 72 (22) | 274 (21) | 39 (2) | 12 (1) |
|
| ||||
| Race - n (%) | ||||
| Caucasian | 310 (94) | 1200 (94) | 1798 (94) | 1404 (91) |
| African American | 6 (2) | 33 (3) | 63 (3) | 56 (4) |
| Asian/Pacific Islander | 3 (1) | 12 (1) | 22 (1) | 28 (2) |
| Native American | 0 | 1 (<1) | 4 (<1) | 8 (1) |
| Other1 | 6 (2) | 17 (1) | 0 | 0 |
| More than one race | 0 | 2 (<1) | 6 (<1) | 6 (<1) |
| Missing | 6 (2) | 18 (1) | 29 (2) | 44 (3) |
|
| ||||
| Remission status at autoHCT - n (%) | ||||
| Complete remission | 209 (63) | 941 (73) | 1528 (80) | 1338 (87) |
| Partial remission | 73 (22) | 268 (21) | 371 (19) | 195 (13) |
| Resistant | 8 (2) | 20 (2) | 18 (1) | 12 (1) |
| Untreated/missing | 41 (13) | 54 (4) | 5 (<1) | 1 (<1) |
|
| ||||
| Graft type - n (%) | ||||
| Bone marrow | 1 (<1) | 14 (1) | 2 (<1) | 0 |
| Peripheral blood | 320 (97) | 1265 (99) | 1920 (100) | 1546 (100) |
| Missing | 10 (3) | 4 (<1) | 0 | 0 |
|
| ||||
| Conditioning regimen - n (%) | ||||
| BEAM | 23 (7) | 354 (28) | 1252 (65) | 1274 (82) |
| CBV | 69 (21) | 299 (23) | 372 (19) | 96 (6) |
| TBI-based | 75 (23) | 116 (9) | 92 (5) | 19 (1) |
| Others | 119 (36) | 396 (31) | 185 (10) | 144 (9) |
| Missing | 45 (14) | 118 (9) | 21 (1) | 13 (1) |
|
| ||||
| AlloHCT after relapse - n (%) | ||||
| No relapse | 185 (56) | 573 (45) | 995 (52) | 1237 (80) |
| No | 114 (34) | 588 (46) | 751 (39) | 275 (18) |
| Yes | 32 (10) | 122 (10) | 176 (9) | 34 (2) |
|
| ||||
| Rituximab in maintenance – n (%) | ||||
|
| ||||
| No | 88 (27) | 215 (17) | 164 (9) | 70 (5) |
|
| ||||
| Yes | 3 (1) | 37 (3) | 33 (2) | 71 (5) |
|
| ||||
| Not available at TED level | 240 (73) | 1031 (80) | 1725 (90) | 1405 (91) |
|
| ||||
| Median overall survival, months | 89 | 137 | NR | NR |
|
| ||||
| Median follow-up of survivors, months (range) | 168 (3–217) | 120 (3–178) | 72 (3–116) | 24 (3–55) |
Abbreviations: HCT: hematopoietic cell transplant; KPS = Karnofsky performance status; BEAM = carmustine, etoposide, cytarabine, melphalan; CBV = cyclophosphamide, carmustine, etoposide; TBI = total body irradiation; AlloHCT = allogeneic hematopoietic cell transplantation; TED = transplant essential data; NR = not reached
1
Race: Other: 2000–2004: 5 Hispanic, race NOS; 1 other race NOS. 2005–2009: 4 Hispanic, race NOS; 13 other race NOS.